Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation
Research output: Contribution to journal › Article › peer-review
49Scopus
citations
Fingerprint
Dive into the research topics of 'Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation'. Together they form a unique fingerprint.